請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70229
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 姜至剛(Chih- Kang Chiang) | |
dc.contributor.author | Ting-wei Mai | en |
dc.contributor.author | 麥庭威 | zh_TW |
dc.date.accessioned | 2021-06-17T04:24:32Z | - |
dc.date.available | 2021-09-04 | |
dc.date.copyright | 2018-09-04 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-15 | |
dc.identifier.citation | 1. Fan J, Kou X, Jia S, Yang X, Yang Y, and Chen N. Autophagy as a Potential Target for Sarcopenia. Journal of cellular physiology. 2016;231(7):1450-9.
2. Marcell TJ. Sarcopenia: causes, consequences, and preventions. The journals of gerontology Series A, Biological sciences and medical sciences. 2003;58(10):M911-6. 3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing. 2010;39(4):412-23. 4. Kim TN, and Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. Journal of bone metabolism. 2013;20(1):1-10. 5. Chal J, and Pourquie O. Making muscle: skeletal myogenesis in vivo and in vitro. Development (Cambridge, England). 2017;144(12):2104-22. 6. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, and Butler-Browne GS. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. Journal of cell science. 1999;112 ( Pt 17):2895-901. 7. Dedieu S, Mazeres G, Cottin P, and Brustis JJ. Involvement of myogenic regulator factors during fusion in the cell line C2C12. The International journal of developmental biology. 2002;46(2):235-41. 8. McCullagh KJ, and Perlingeiro RC. Coaxing stem cells for skeletal muscle repair. Advanced drug delivery reviews. 2015;84:198-207. 9. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of internal medicine. 2010;268(5):456-67. 10. Bauer C, Melamed ML, and Hostetter TH. Staging of chronic kidney disease: time for a course correction. Journal of the American Society of Nephrology : JASN. 2008;19(5):844-6. 11. Stenvinkel P, and Larsson TE. Chronic kidney disease: a clinical model of premature aging. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;62(2):339-51. 12. Moorthi RN, and Avin KG. Clinical relevance of sarcopenia in chronic kidney disease. Current opinion in nephrology and hypertension. 2017;26(3):219-28. 13. Carrero JJ, Chmielewski M, Axelsson J, Snaedal S, Heimburger O, Barany P, et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clinical nutrition (Edinburgh, Scotland). 2008;27(4):557-64. 14. Souza VA, Oliveira D, Mansur HN, Fernandes NM, and Bastos MG. Sarcopenia in chronic kidney disease. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2015;37(1):98-105. 15. Chao CT, and Chiang CK. Uremic toxins, oxidative stress, and renal fibrosis: an interwined complex. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2015;25(2):155-9. 16. Lekawanvijit S, Kompa AR, and Krum H. Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome. American journal of physiology Renal physiology. 2016;311(1):F52-62. 17. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney international. 2003;63(5):1934-43. 18. Glassock RJ. Uremic toxins: what are they? An integrated overview of pathobiology and classification. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2008;18(1):2-6. 19. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, and Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Analytical and bioanalytical chemistry. 2012;403(7):1841-50. 20. Sakai T, Takadate A, and Otagiri M. Characterization of binding site of uremic toxins on human serum albumin. Biological & pharmaceutical bulletin. 1995;18(12):1755-61. 21. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2011;15(2):120-4. 22. Chiang CK, Tanaka T, and Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2012;22(1):77-80. 23. Leong SC, and Sirich TL. Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins. 2016;8(12). 24. Nallu A, Sharma S, Ramezani A, Muralidharan J, and Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. Translational research : the journal of laboratory and clinical medicine. 2017;179:24-37. 25. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, and Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney international Supplement. 1997;62:S23-8. 26. Jenq RR. How's your microbiota? Let's check your urine. Blood. 2015;126(14):1641-2. 27. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2010;20(5 Suppl):S2-6. 28. Vanholder R, Schepers E, Pletinck A, Nagler EV, and Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. Journal of the American Society of Nephrology : JASN. 2014;25(9):1897-907. 29. Nishikawa M, Ishimori N, Takada S, Saito A, Kadoguchi T, Furihata T, et al. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30(6):934-42. 30. Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y, et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Scientific reports. 2016;6:32084. 31. Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, et al. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. Journal of cachexia, sarcopenia and muscle. 2017;8(5):735-47. 32. Sato E, Mori T, Mishima E, Suzuki A, Sugawara S, Kurasawa N, et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Scientific reports. 2016;6:36618. 33. Levine B, and Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27-42. 34. Mizushima N, Levine B, Cuervo AM, and Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069-75. 35. Kaur J, and Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nature reviews Molecular cell biology. 2015;16(8):461-72. 36. Mizushima N, Yoshimori T, and Levine B. Methods in mammalian autophagy research. Cell. 2010;140(3):313-26. 37. Klionsky DJ, Cregg JM, Dunn WA, Jr., Emr SD, Sakai Y, Sandoval IV, et al. A unified nomenclature for yeast autophagy-related genes. Developmental cell. 2003;5(4):539-45. 38. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nature reviews Molecular cell biology. 2001;2(3):211-6. 39. Kim KH, and Lee MS. Autophagy--a key player in cellular and body metabolism. Nature reviews Endocrinology. 2014;10(6):322-37. 40. Cicchini M, Karantza V, and Xia B. Molecular pathways: autophagy in cancer--a matter of timing and context. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(3):498-504. 41. Glick D, Barth S, and Macleod KF. Autophagy: cellular and molecular mechanisms. The Journal of pathology. 2010;221(1):3-12. 42. Levine B. Autophagy and cancer. Nature. 2007;446:745. 43. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Kim SS, et al. Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. The Journal of pathology. 2009;217(5):702-6. 44. Masini M, Bugliani M, Lupi R, del Guerra S, Boggi U, Filipponi F, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia. 2009;52(6):1083-6. 45. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441(7095):885-9. 46. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141(7):1146-58. 47. Sin J, Andres AM, Taylor DJ, Weston T, Hiraumi Y, Stotland A, et al. Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts. Autophagy. 2016;12(2):369-80. 48. Fortini P, Ferretti C, Iorio E, Cagnin M, Garribba L, Pietraforte D, et al. The fine tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell death & disease. 2016;7:e2168. 49. Fortini P, Iorio E, Dogliotti E, and Isidoro C. Coordinated Metabolic Changes and Modulation of Autophagy during Myogenesis. Frontiers in physiology. 2016;7:237. 50. Su Z, Klein JD, Du J, Franch HA, Zhang L, Hassounah F, et al. Chronic kidney disease induces autophagy leading to dysfunction of mitochondria in skeletal muscle. American journal of physiology Renal physiology. 2017;312(6):F1128-f40. 51. Tait SW, and Green DR. Mitochondria and cell signalling. Journal of cell science. 2012;125(Pt 4):807-15. 52. Youle RJ, and van der Bliek AM. Mitochondrial fission, fusion, and stress. Science (New York, NY). 2012;337(6098):1062-5. 53. Russell AP, Foletta VC, Snow RJ, and Wadley GD. Skeletal muscle mitochondria: a major player in exercise, health and disease. Biochimica et biophysica acta. 2014;1840(4):1276-84. 54. Puigserver P, and Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocrine reviews. 2003;24(1):78-90. 55. Chacinska A, Koehler CM, Milenkovic D, Lithgow T, and Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell. 2009;138(4):628-44. 56. MacVicar T, and Langer T. OPA1 processing in cell death and disease - the long and short of it. Journal of cell science. 2016;129(12):2297-306. 57. Wagatsuma A, and Sakuma K. Mitochondria as a potential regulator of myogenesis. TheScientificWorldJournal. 2013;2013:593267. 58. Remels AH, Langen RC, Schrauwen P, Schaart G, Schols AM, and Gosker HR. Regulation of mitochondrial biogenesis during myogenesis. Molecular and cellular endocrinology. 2010;315(1-2):113-20. 59. Ding WX, and Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biological chemistry. 2012;393(7):547-64. 60. Gatica D, Lahiri V, and Klionsky DJ. Cargo recognition and degradation by selective autophagy. Nature cell biology. 2018;20(3):233-42. 61. Youle RJ, and Narendra DP. Mechanisms of mitophagy. Nature reviews Molecular cell biology. 2011;12(1):9-14. 62. Gkikas I, Palikaras K, and Tavernarakis N. The Role of Mitophagy in Innate Immunity. Frontiers in immunology. 2018;9:1283. 63. Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, and Zhang J. Mitophagy mechanisms and role in human diseases. The international journal of biochemistry & cell biology. 2014;53:127-33. 64. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445-544. 65. Jheng JR, Chen YS, Ao UI, Chan DC, Huang JW, Hung KY, et al. The double-edged sword of endoplasmic reticulum stress in uremic sarcopenia through myogenesis perturbation. Journal of cachexia, sarcopenia and muscle. 2018. 66. Wang XH, and Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nature reviews Nephrology. 2014;10(9):504-16. 67. Lecker SH, Goldberg AL, and Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. Journal of the American Society of Nephrology : JASN. 2006;17(7):1807-19. 68. Rashid HO, Yadav RK, Kim HR, and Chae HJ. ER stress: Autophagy induction, inhibition and selection. Autophagy. 2015;11(11):1956-77. 69. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. The Journal of cell biology. 2005;171(4):603-14. 70. Chen Y, and Gibson SB. Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy. 2008;4(2):246-8. 71. Scherz-Shouval R, and Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends in biochemical sciences. 2011;36(1):30-8. 72. Azad MB, Chen Y, and Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxidants & redox signaling. 2009;11(4):777-90. 73. Filomeni G, De Zio D, and Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell death and differentiation. 2015;22(3):377-88. 74. Motojima M, Hosokawa A, Yamato H, Muraki T, and Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney international. 2003;63(5):1671-80. 75. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, and Miyazaki H. ROS and PDGF-beta [corrected] receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. American journal of physiology Cell physiology. 2009;297(2):C389-96. 76. Wu Q, Gao C, Wang H, Zhang X, Li Q, Gu Z, et al. Mdivi-1 alleviates blood-brain barrier disruption and cell death in experimental traumatic brain injury by mitigating autophagy dysfunction and mitophagy activation. The international journal of biochemistry & cell biology. 2018;94:44-55. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70229 | - |
dc.description.abstract | 尿毒肌少症(Uremic sarcopenia)是常見於慢性腎臟病(Chronic kidney disease, CKD)患者的肌肉耗損症狀,經研究證實會增加CKD患者的死亡率。因此,發展治療尿毒症肌少症的方法顯得格外重要。然而,目前對於CKD造成肌少症的致病分生機制仍未明確。先前研究顯示,硫酸吲哚酚(Indoxyl sulfate, IS)為一種親蛋白質尿毒素,會抑制骨骼肌細胞分化。研究指出IS會使肌肉細胞的粒線體功能受損,並藉由增加氧化壓力改變細胞的代謝進而使骨骼肌細胞萎縮,最終造成肌少症。近期研究證實,骨骼肌細胞在分化初期會活化細胞自噬作用,在分化後期則會回復至一般生理狀態。然而,細胞自噬受損是否為尿毒症肌少症的致病機轉仍不清楚。在本篇研究中,我們推測尿毒素可能藉由損害細胞自噬而抑制肌肉生成。為了證實此假設並闡明其中的機制作用,我們使用IS處理小鼠肌纖維母細胞(C2C12 myoblast),探討其對於分化過程中細胞自噬的影響。本研究主要利用西方點墨法(Western Blot)和即時定量聚合酶連鎖反應(Real-time Quantitative PCR)分析與分化、細胞自噬及粒線體功能相關的指標。研究結果顯示,透過LC3 turnover assay可證實,在C2C12分化過程中IS的處理會誘發完整的細胞自噬作用。基於初步的結果,我們進而探討IS誘導的細胞自噬是否會進一步影響到粒線體自噬、粒線體功能及粒線體動態平衡。結果顯示C2C12粒線體內的粒線體自噬指標p62表現量在IS處理後會上升,粒線體功能指標PGC-1α、TOM70以及粒線體動態平衡指標OPA1的表現量則會下降。綜合上述,本研究指出IS的暴露可能會造成細胞自噬失調而干擾骨骼肌細胞的分化,且IS造成的粒線體功能與粒線體動態平衡損害,可能與分化過程中誘發的粒線體自噬有關。然而,未來仍需要更多研究去釐清IS誘導之細胞自噬與粒線體自噬的詳細分子機轉。 | zh_TW |
dc.description.abstract | Uremic sarcopenia is a muscle wasting syndrome that often observed in chronic kidney disease (CKD) patients, which is associated with increased mortality. Therefore, developing therapeutic strategy for treating CKD-associated sarcopenia is important. However, the underlying molecular mechanism of CKD-associated sarcopenia is still poorly understood. Our previous study demonstrated that indoxyl sulfate (IS), one of the protein-bound uremic toxins, dysregulates myogenic differentiation. Other studies also showed that IS strongly accelerates skeletal muscle atrophy through oxidative stress-mediated metabolism alteration, which in turn adversely contribute to sarcopenia. It has been demonstrated that IS also induces mitochondria dysfunction in skeletal muscle cells. Currently, physiologic activation of autophagy has been reported in skeletal muscles. However, whether impaired autophagy involved in uremic sarcopenia remains unclear. In this study, we hypothesized that uremic toxins may exert its anti-myogenesis by impaired autophagy. To verify this hypothesis and elucidate the mechanism, we examined the effects of IS on skeletal muscle differentiation in mouse C2C12 myoblast cells with a focus on alterations in autophagic process. The expression of myogenic differentiation markers, autophagy-related markers, mitochondria -related markers were determined by western blotting and quantitative PCR. Our results indicated that IS treatment induces a complete autophagy as demonstrated by LC3 turnover assay. Based on the preliminary data, we further explore whether the IS-induced autophagy interferes the mitophagy, mitochondrial functions and dynamic. We observed that the expression of p62 levels, which is a mitophagy marker, were increased in the mitochondria extracts from IS-treated C2C12 cells, which accompanied with the decrease of the levels of mitochondrial function markers, PGC-1α, TOM70 and dynamic marker, OPA1. In conclusion, the present study indicated that IS exposure might interfere with myoblast differentiation by dysregulation of autophagy. And the exposure of IS might impair the mitochondrial functions and dynamics, which associated with the induction of mitophagy in C2C12 differentiation. However, further experiments are indicated to clarify the molecular mechanisms, which are responsible for IS-induced autophagy and mitophagy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:24:32Z (GMT). No. of bitstreams: 1 ntu-107-R05447005-1.pdf: 4377853 bytes, checksum: ac5a3ddd66a88de0b75658a6572bb909 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iv Abstract vi Abbreviation Summary viii Part I. Introduction 1 1.1 Sarcopenia 1 1.2 Skeletal muscle myogenesis 1 1.3 Chronic kidney disease 2 1.4 Uremic toxins 4 1.5 Indoxyl sulfate 5 1.6 Autophagy 7 1.7 Mitochondria 10 1.8 Mitophagy 11 Part II. Aim 14 Part III. Materials and Methods 15 3.1 Cell culture 15 3.2 Immunoblotting analysis 15 3.3 Quantification of mRNA by real-time quantitative reverse transcription PCR 18 3.4 Hematoxylin and eosin (H&E) staining 19 3.5 Measurement of autophagy 19 3.6 Immunofluorescence assays 20 3.7 Statistical analysis 20 Part IV. Results 22 4.1 Indoxyl sulfate enhances autophagy during C2C12 differentiation. 22 4.2 Indoxyl sulfate treatment enhances a complete autophagy as demonstrated by LC3 turnover assay. 23 4.3 Indoxyl sulfate treatment has no effect on other autophagy markers, such as Beclin-1, Atg5 and p62 during C2C12 myogenesis. 24 4.4 Effect of indoxyl sulfate on mitochondrial functions and mitochondrial dynamic in whole-cell extracts from C2C12 cells during differentiation. 25 4.5 Indoxyl sulfate induces mitophagy and impaires mitochondrial functions in mitochondria extracts from differentiated C2C12 cells. 26 4.6 Indoxyl sulfate induces muscle atrophy, but has no effect on autophagy in C2C12 myotubes. 28 4.7 NAC reverses IS-enhanced autophagy in C2C12 differentiation. 29 Part V. Discussions 30 Part VI. Conclusion 37 Part VII. Future perspectives 38 Part VIII. References 40 Part IX. Figures 52 Figure 1. Indoxyl sulfate inhibits the differentiation of C2C12 cells. 53 Figure 2. Indoxyl sulfate enhances autophagy during the C2C12 differentiation. 54 Figure 3. Indoxyl sulfate treatment enhances a complete autophagy as demonstrated by LC3 turnover assay. 56 Figure 4. Indoxyl sulfate enhances autophagy in differentiated C2C12 cells. 57 Figure 5. Indoxyl sulfate treatment has no effect on other autophagy markers, such as Beclin-1, Atg5 and p62 in differentiated C2C12 cells. 58 Figure 6. Effect of indoxyl sulfate on mitochondrial functions and mitochondrial dynamic in C2C12 cells during differentiation. 60 Figure 7. Indoxyl sulfate induces mitophagy and impairs mitochondrial functions in mitochondria extracts from differentiated C2C12 cells. 62 Figure 8. Indoxyl sulfate inhibits the expression of TOM70 in differentiated C2C12 cells. 64 Figure 9. Indoxyl sulfate induces muscle atrophy, but has no effect on autophagy in C2C12 myotubes. 65 Figure 10. NAC reverses IS-enhanced autophagy in C2C12 differentiation. 67 Part X. Supplementary figures 68 Supplementary figure 1. Rapamycin and indoxyl sulfate treatment enhances autophagy and decreased MHC expression during C2C12 differentiation. 68 Supplementary figure 2. The effect of the different concentration of autophagy inhibitor 3-MA in C2C12 cells. 69 Supplementary figure 3. The effect of LC3 knockdown in C2C12 cells. 70 | |
dc.language.iso | en | |
dc.title | 細胞自噬在硫酸吲哚酚誘發尿毒肌少症的角色強調細胞機轉 | zh_TW |
dc.title | The Roles of Autophagy in Indoxyl Sulfate-induced Uremic Sarcopenia Emphasize in Cellular Mechanisms | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 劉興華(Shing-Hwa Liu),許美鈴(Shoei-Yn Lin-ShiauMeei-Ling Sheu),蕭水銀(Shoei-Yn Lin-Shiau) | |
dc.subject.keyword | 硫酸??酚,慢性腎臟病,肌少症,骨骼肌,分化,細胞自噬,粒線體,粒線體自噬, | zh_TW |
dc.subject.keyword | Chronic kidney disease,Sarcopenia,Indoxyl sulfate,Differentiation,autophagy,Mitophagy,Mitochondria, | en |
dc.relation.page | 70 | |
dc.identifier.doi | 10.6342/NTU201803584 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 4.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。